Current and emerging therapeutic targets for IBD
Friedrich-Alexander-Universität Erlangen-Nürnberg
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
674
total citations
- FWCI
- 50.93
- Percentile
- 100%
- References
- 155
Citations per year
Authors
1Topics & keywords
Topics
Keywords
- Medicine
- Vedolizumab
- Apremilast
- Clinical trial
- Azathioprine
- Pharmacology
- Immunology
- Inflammatory bowel disease
No related works found for this paper.